{
 "checked": "2026-10-23 (America/New_York)",
 "page": "https://jabbitapp.com/research/survodutide-weight-loss-synchronize-teardown.html",
 "synchronize_1": {
  "n": 725,
  "weeks": 76,
  "treatment_regimen_pct": {
   "3.6mg": -12.2,
   "6.0mg": -13.0,
   "placebo": -5.4
  },
  "efficacy_estimand_pct": {
   "3.6mg": -15.3,
   "6.0mg": -16.6,
   "placebo": -3.2
  },
  "ge5pct": {
   "3.6mg": 72.6,
   "6.0mg": 71.9,
   "placebo": 46.3
  },
  "gi_ae_pct": {
   "3.6mg": 80.9,
   "6.0mg": 89.7,
   "placebo": 47.9
  },
  "gi_discontinuation_pct": {
   "3.6mg": 17.8,
   "6.0mg": 20.2,
   "placebo": 2.9
  },
  "heart_rate_bpm": "+3.2 to +3.5 at week 76 (AJMC)",
  "placebo_prohibited_glp1_use": ">16% (AJMC)",
  "src": [
   "https://www.nejm.org/doi/full/10.1056/NEJMoa2600751",
   "https://www.ajmc.com/view/survodutide-phase-3-data-signal-metabolic-gains-beyond-weight-loss"
  ]
 },
 "synchronize_2": {
  "n_analyzed": 752,
  "n_enrolled_per_bi": 755,
  "weeks": 76,
  "baseline_hba1c": 7.4,
  "insulin_users": "excluded (TCTMD)",
  "treatment_regimen_pct": {
   "3.6mg": -8.2,
   "6.0mg": -9.8,
   "placebo": -3.9
  },
  "efficacy_estimand_up_to_pct": {
   "survodutide_dose_not_stated_by_bi": -13.1,
   "placebo": -3.1
  },
  "ge5pct": {
   "3.6mg": 57.6,
   "6.0mg": 64.5,
   "placebo": 35.1
  },
  "gi_ae_pct": {
   "3.6mg": 72.8,
   "6.0mg": 77.7,
   "placebo": 38.6
  },
  "gi_discontinuation_pct": {
   "survodutide_pooled": 18,
   "placebo": 1.2
  },
  "src": [
   "https://www.nejm.org/doi/full/10.1056/NEJMoa2607219",
   "https://www.globenewswire.com/news-release/2026/10/01/3372564/0/en/boehringer-ingelheim-s-survodutide-achieves-up-to-13-1-weight-loss-in-new-phase-iii-trial-alongside-significant-improvements-in-glycemic-control-in-people-with-obesity-and-type-2-d.html"
  ]
 },
 "comparators": {
  "no_diabetes": {
   "wegovy_step1_label_diff": 12.4,
   "zepbound_15mg_surmount1_label_diff": 17.8,
   "retatrutide_12mg_triumph1_diff": 21.0
  },
  "type_2_diabetes": {
   "wegovy_step2_label_diff": 6.2,
   "zepbound_15mg_surmount2_label_diff": 11.6,
   "retatrutide_12mg_triumph2_etd": 13.8
  },
  "all_cause_ae_discontinuation_pct": {
   "wegovy_2.4mg_inj_label": 6.8,
   "zepbound_15mg_label": 6.7,
   "retatrutide_12mg_triumph2_ae_or_death": 8
  },
  "heart_rate_label_bpm": {
   "wegovy_injection": "1 to 4",
   "zepbound": "1 to 3"
  },
  "src": [
   "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf",
   "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf",
   "https://pubmed.ncbi.nlm.nih.gov/42814954/",
   "https://pubmed.ncbi.nlm.nih.gov/42810372/"
  ]
 },
 "jabbit_analysis": {
  "survodutide_6mg_placebo_adjusted_points_treatment_regimen": {
   "no_diabetes": 7.6,
   "type_2_diabetes": 5.9
  },
  "survodutide_6mg_placebo_adjusted_points_efficacy_estimand_no_diabetes": 13.4,
  "gi_only_quit_rate_vs_all_cause_label_rates": "survodutide GI-only 17.8-20.2% vs 6.7-8% all-cause on Wegovy/Zepbound labels and TRIUMPH-2, about 2-3x",
  "caveat": "Cross-trial, not head-to-head; different populations, durations (68-80 weeks) and placebo results."
 },
 "milestones": {
  "synchronize_cvot": {
   "nct": "NCT06077864",
   "status": "Completed (ClinicalTrials.gov)",
   "treated": 5508,
   "presentation": "AHA Scientific Sessions LBS.05, 2026-11-09 08:00-09:15 CT",
   "src": "https://professional.heart.org/en/meetings/scientific-sessions/programming/late-breaking-science"
  },
  "regulatory_filing": "None announced as of 2026-10-23 that we found; BI 'too early to set a timeline' (MedWatch, May 1, 2026)",
  "zealand_lean_loss_ratio": "updated from 10.8% to 11.3% following a recalculation (Zealand H1 2026, Aug 13, 2026)"
 }
}